Filing summary
Entity and period: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed March 28, 2024. It is not a filing for Solana Co.; the requested company name does not match the registrant in the filing. The filing reports full-year results, not a standalone 2023 fourth quarter.
Business context
Helius is a neurotechnology company whose principal product is PoNS, a non-implantable device used with supervised therapeutic exercise. At year-end, PoNS was authorized in the U.S. for gait deficit associated with mild-to-moderate multiple sclerosis (MS), and in Canada for specified MS, traumatic brain injury and stroke indications. It was also authorized in Australia, but the company reported no Australian commercial sales. U.S. sales began in April 2022; Canadian commercialization began in 2019.
Key financial metrics
| Metric (USD millions, except per-share amounts) | 2023 | 2022 |
|---|---|---|
| Total revenue | $0.644 | $0.787 |
| Product sales | $0.605 | $0.778 |
| Gross profit / gross margin | $0.061 / 9.5% | $0.324 / 41.2% |
| Operating expenses | $12.489 | $15.840 |
| Operating loss | $(12.428) | $(15.516) |
| Net loss | $(8.850) | $(14.072) |
| Net cash used in operating activities | $(10.416) | $(14.310) |
| Cash and cash equivalents at year-end | $5.182 | $14.549 |
| Working capital at year-end | $5.559 | $14.709 |
Revenue fell about 18%, largely reflecting lower Canadian sales; the prior-year comparison included approximately $0.120 million from delivery of devices received as noncash acquisition consideration. Gross profit fell as lower sales volume absorbed less fixed overhead, while cost of revenue increased. Operating expenses declined, including lower selling, general and administrative and research and development costs. Net loss improved partly because of noncash warrant-related fair-value gains and lower expenses; the $2.966 million derivative-liability gain in 2023 was not operating cash generation.
The balance sheet showed total liabilities of $5.342 million, including a $3.323 million derivative liability for warrants and operating lease liabilities; the filing reports no conventional borrowings. Cash declined by $9.367 million during 2023. Financing provided $1.077 million, including ATM share sales and warrant exercises; the company reported 714,590 shares outstanding at year-end after a 1-for-50 reverse split.
Material changes, outlook and risks
- Funding and going concern: The auditor’s report and management state that recurring losses and financing needs raise substantial doubt about the company’s ability to continue as a going concern. Management expected existing resources, including $1.3 million net ATM proceeds raised in 2024 through the filing date, to fund operations only through the second quarter of 2024. Further financing is required; availability and terms are uncertain.
- Reimbursement: CMS assigned HCPCS codes for the PoNS controller and mouthpiece in February 2024, effective April 1, 2024. The codes do not themselves establish Medicare coverage or payment. Management planned to seek Medicare payment determinations in the second half of 2024 and estimated broad payer coverage could take at least 24 months after code effectiveness. U.S. sales had primarily depended on self-paying patients.
- Commercialization and trials: Management planned to continue U.S. commercialization and reimbursement efforts, Canadian clinic activity, and clinical research. Stroke studies were underway or planned, with enrollment targeted to finish by the end of 2024 and an FDA submission targeted for mid-to-late 2025. A prior FDA de novo application for the mmTBI indication was denied; further work depends on financing.
- Manufacturing: The company began moving production from Key Tronic to Minnetronix in 2023 and expected the transition to finish by mid-2024. Delays, quality problems or supply disruption could affect sales.
- Other risks and unusual items: The company has one commercial product, limited revenue, customer concentration (two customers accounted for 65% of 2023 product sales), and reliance on third parties for manufacturing and distribution. It recorded a $0.159 million fixed-asset impairment in 2023; 2022 included a $0.757 million goodwill impairment. A $0.5 million employee retention credit was recorded in 2023, with receipt expected within 12 months.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co.
- Review subsequent financing, cash balances and operating cash use, particularly against the stated Q2 2024 funding horizon and going-concern uncertainty.
- Check whether HCPCS codes led to actual Medicare payment determinations, payer coverage, reimbursement rates or increased sales.
- Track PoNS revenue, gross margin, customer concentration and evidence of repeatable patient demand beyond self-pay sales.
- Verify completion and performance of the Minnetronix manufacturing transition and progress, funding and regulatory outcomes for stroke trials.